We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+41.28%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$907M
AUM Growth
+$202M
Cap. Flow
-$185K
Cap. Flow %
-0.02%
Top 10 Hldgs %
41.16%
Holding
93
New
10
Increased
12
Reduced
5
Closed
9

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$15.3M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$13.9M
3
KA
Kineta, Inc. Common Stock
KA
+$13.2M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$10.9M
5
MTVA
MetaVia Inc
MTVA
+$10M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$30.5M
2
NKTR icon
Nektar Therapeutics
NKTR
+$28.8M
3
SAGE
Sage Therapeutics
SAGE
+$22M
4
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$18.9M
5
NVAX icon
Novavax
NVAX
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 91.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
1
DELISTED
Alder Biopharmaceuticals
ALDR
$55.4M 6.1%
1,689,071
– –
NVRO
2
DELISTED
NEVRO CORP.
NVRO
$51.3M 5.65%
491,044
– –
TBPH icon
3
Theravance Biopharma
TBPH
$873M
$40.5M 4.47%
1,118,372
– –
NERV icon
4
Minerva Neurosciences
NERV
$191M
$39.5M 4.36%
350,000
– –
KA
5
DELISTED
Kineta, Inc. Common Stock
KA
$36.6M 4.04%
16,786
+7,112
+74% +$13.2M
CLSD
6
DELISTED
Clearside Biomedical
CLSD
$34.5M 3.8%
132,547
– –
EGRX
7
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$31.9M 3.52%
455,995
-50,000
-10% -$2.77M
HRTX icon
8
Heron Therapeutics
HRTX
$93.4M
$30.5M 3.37%
1,771,263
– –
ARDX icon
9
Ardelyx
ARDX
$1.24B
$26.8M 2.96%
2,071,964
+572,738
+38% +$6M
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$26.2M 2.89%
1,605,790
+847,500
+112% +$15.3M
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$23.4M 2.58%
+650,000
New +$13.9M
ACRS icon
12
Aclaris Therapeutics
ACRS
$715M
$23.1M 2.55%
901,286
– –
QTNT
13
DELISTED
Quotient Limited Ordinary Shares
QTNT
$21.8M 2.4%
69,693
+31,250
+81% +$8.79M
LKFT
14
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$21.4M 2.36%
334,044
– –
MGNX icon
15
MacroGenics
MGNX
$233M
$21.2M 2.34%
707,978
– –
NBIX icon
16
Neurocrine Biosciences
NBIX
$18.2B
$20.2M 2.22%
398,301
– –
OMER icon
17
Omeros
OMER
$845M
$18.9M 2.09%
1,695,000
-15,000
-0.9% -$171K
PTGX icon
18
Protagonist Therapeutics
PTGX
$8.55B
$16.9M 1.86%
+800,000
New +$10.9M
WVE icon
19
Wave Life Sciences
WVE
$1.12B
$16.5M 1.82%
507,907
+113,500
+29% +$2.68M
SRNE
20
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$16.4M 1.81%
2,121,013
– –
CHRS icon
21
Coherus Oncology
CHRS
$217M
$15.4M 1.7%
576,106
– –
CBPO
22
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$14.1M 1.55%
112,867
– –
CRBP icon
23
Corbus Pharmaceuticals
CRBP
$165M
$13.6M 1.5%
66,667
– –
PTLA
24
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$13.5M 1.49%
596,000
+200,000
+51% +$4.69M
CLLS
25
Cellectis
CLLS
$288M
$12M 1.32%
498,117
– –
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2016 Portfolio in Review

As of Q3 2016, Cormorant Asset Management held 93 positions worth $907M, up 29% from $705M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management's Q3 2016 filing shows 10 new, 12 increased, 5 reduced and 9 closed positions. Its largest new stake was Clovis Oncology, Inc.: 650,000 shares worth $23.4M. The largest sale was TESARO, Inc., an estimated $30.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier.

  • Cormorant Asset Management's largest Q3 2016 buy was Clovis Oncology, Inc.: 650,000 shares worth $23.4M.
  • Cormorant Asset Management added most to MyoKardia, Inc. Common Stock in Q3 2016, an estimated $15.3M increase.
  • Cormorant Asset Management's biggest Q3 2016 reduction was Alnylam Pharmaceuticals, cutting an estimated $5.24M.
  • Cormorant Asset Management fully exited TESARO, Inc. in Q3 2016, selling an estimated $30.5M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $907M portfolio in Q3 2016.
  • Cormorant Asset Management opened 10 new positions and closed 9 in Q3 2016.
  • Cormorant Asset Management's portfolio value rose 29% quarter-over-quarter to $907M.

Based on Cormorant Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.